Table 8.
CXCR2 inhibitors in selected clinical trials. Source: ClinicalTrials.gov NIH U.S. National Library of Medicine website.
| Disease for Which the Drug Is Being Tested | Drug Name | Clinical Trial Phase | ClinicalTrials.gov Identifier |
|---|---|---|---|
| Metastatic Castration-Resistant Prostate Cancer | AZD5069 | I and II | NCT03177187 |
| Myelodysplastic Syndromes | SX-682 | I | NCT04245397 |
| Pancreatic Ductal Adenocarcinoma | SX-682 | I | NCT04477343 |
| Melanoma Stage III and Stage IV | SX-682 | I | NCT03161431 |
| Inflammatory Response | RIST4721 | I | NCT04105959 |
| Chronic Obstructive Pulmonary Disease (COPD) | Danirixin (GSK1325756) | I | NCT01453478 |
| COPD | Danirixin (GSK1325756) | I | NCT03136380 |
| COPD | Danirixin (GSK1325756) | II | NCT03250689 |
| COPD | Danirixin (GSK1325756) | II | NCT02130193 |
| COPD | Navarixin (SCH 527123, MK-7123) | II | NCT01006616 |
| COPD | QBM076 | II | NCT01972776 |
| Influenza | Danirixin (GSK1325756) | II | NCT02469298 |
| Influenza | Danirixin (GSK1325756) | II | NCT02927431 |
| Respiratory Syncytial Virus (RSV) Infections | Danirixin (GSK1325756) | I | NCT02201303 |
| COPD | SB-656933 | I | NCT00504439 |
| Cystic Fibrosis | SB-656933 | II | NCT00903201 |
| Type 1 Diabetes | Ladarixin | II | NCT05035368 |
| Type 1 Diabetes | Ladarixin | III | NCT04628481 |
| Bullous Pemphigoid | DF2156A | II | NCT01571895 |